Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Hits Sweet Spot On Checkpoint Inhibitor Combination Pricing

This article was originally published in The Pink Sheet Daily

Executive Summary

Decision to price combo of Yervoy and Opdivo at just 6% more than Yervoy monotherapy could set a trend for the market.


Related Content

Keytruda's Broad Confirmatory Trials Suggest Evolution Of US FDA’s Accelerated Approval Model
Bristol Taking A Cautious Approach To Triple Immuno-Oncology Combos
Melanoma Approvals Break New Ground In Immunotherapy
Bristol Offers Yervoy For Free In New Early Melanoma Indication
How To Catch The Next Wave Of Cancer Immunotherapy
Nektar Edges Into Immunotherapy With Better Interleukin-2 Drug
Keeping Track: Sanofi Submits Lixisenatide NDA (Again); Sandoz Files Second Biosimilar Application
Keytruda NSCLC Approval Will Test PD-L1 Expression
Ipilimumab Boosts Survival, But With Adverse Events That Need Strict Oversight


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts